You are here: Industry Insights > Libtayo

News List

Libtayo® with chemotherapy trial stopped early due to success europeanpharmaceuticalreview
August 10, 2021
Phase III trial of Libtayo® (cemiplimab) combined with chemotherapy stops early due to significant improvement in overall survival in lung cancer patients.
Sanofi and Regeneron’s Libtayo trial stops early due to survival improvement pharmatimes
August 09, 2021
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) in combination with platinum-doublet chemotherapy has been stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small cell ...
Sanofi, Regeneron's Libtayo cleared for basal cell carcinoma pharmatimes
June 28, 2021
Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) has won a green light in Europe as the first immunotherapy to treat adults with locally advanced or metastatic basal cell carcinoma (BCC).
mRNA-based therapeutic cancer vaccine enters Phase II trial europeanpharmaceuticalreview
June 24, 2021
BioNTech is evaluating its investigational therapeutic mRNA-based cancer vaccine, BNT111, in combination with Libtayo® (cemiplimab) for the treatment of melanoma.
Libtayo Monotherapy Trial in Advanced Cervical Cancer Stopped Early for OS Positive Result americanpharmaceuticalreview
March 22, 2021
Regeneron Pharmaceuticals and Sanofi announced positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) monotherapy compared to chemotherapy, in patients previously ...
Libtayo® improves overall survival in advanced cervical cancer patients europeanpharmaceuticalreview
March 16, 2021
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients pharmatimes
March 15, 2021
Sanofi and Regeneron’s PD-1 inhibitor Libtayo has demonstrated positive overall survival (OS) results in a Phase III trial in advanced cervical cancer.
FDA Approves Libtayo americanpharmaceuticalreview
February 23, 2021
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high ...
FDA Accepts for Priority Review Libtayo for Advanced Non-small Cell Lung Cancer americanpharmaceuticalreview
November 09, 2020
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo® (cemiplimab-rwlc) to treat patients with ...
Sanofi/Regeneron's Libtayo shows benefit in BCC pharmatimes
May 08, 2020
Sanofi and Regeneron's Libtayo (cemiplimab) has demonstrated 'clinically meaningful and durable responses' in a subset of patients with basal call carcinoma (BCC) from whom there are currently no approved treatments.

Previous page 1 2 Next page